Skip to main content
Top
Published in: Strahlentherapie und Onkologie 1/2014

01-01-2014 | Original article

Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer

The DEGRO-QUIRO trial

Authors: Prof. Dr. L. Keilholz, J. Willner, H.-J. Thiel, N. Zamboglou, H. Sack, W. Popp

Published in: Strahlentherapie und Onkologie | Issue 1/2014

Login to get access

Abstract

Purpose

In order to evaluate resource requirements, the German Society of Radiation Oncology (DEGRO) recorded the times needed for core procedures in the radio-oncological treatment of various cancer types within the scope of its QUIRO trial. The present study investigated the personnel and infrastructural resources required in radiotherapy of prostate cancer.

Methods

The investigation was carried out in the setting of definitive radiotherapy of prostate cancer patients between July and October 2008 at two radiotherapy centers, both with well-trained staff and modern technical facilities at their disposal. Personnel attendance times and room occupancy times required for core procedures (modules) were each measured prospectively by two independently trained observers using time measurements differentiated on the basis of professional group (physician, physicist, and technician), 3D conformal (3D-cRT), and intensity-modulated radiotherapy (IMRT).

Results

Total time requirements of 983 min for 3D-cRT and 1485 min for step-and-shoot IMRT were measured for the technician (in terms of professional group) in all modules recorded and over the entire course of radiotherapy for prostate cancer (72–76 Gy). Times needed for the medical specialist/physician were 255 min (3D-cRT) and 271 min (IMRT), times of the physicist were 181 min (3D-cRT) and 213 min (IMRT). The difference in time was significant, although variations in time spans occurred primarily as a result of various problems during patient treatment.

Conclusion

This investigation has permitted, for the first time, a realistic estimation of average personnel and infrastructural requirements for core procedures in quality-assured definitive radiotherapy of prostate cancer. The increased time needed for IMRT applies to the step-and-shoot procedure with verification measurements for each irradiation planning.
Literature
1.
go back to reference Bentzen SM, Herren G, Cottier B et al (2005) Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75:355–369PubMedCrossRef Bentzen SM, Herren G, Cottier B et al (2005) Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75:355–369PubMedCrossRef
2.
go back to reference Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. The DEGRO-QUIRO trial. Strahlenther Onkol 188:113–119PubMedCrossRef Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. The DEGRO-QUIRO trial. Strahlenther Onkol 188:113–119PubMedCrossRef
3.
go back to reference Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients. The DEGRO-QUIRO trial. Strahlenther Onkol 187:449–460PubMedCrossRef Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients. The DEGRO-QUIRO trial. Strahlenther Onkol 187:449–460PubMedCrossRef
4.
go back to reference Davis BJ, Horwitz EM, Lee WR et al (2012) American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11:6–19PubMedCrossRef Davis BJ, Horwitz EM, Lee WR et al (2012) American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11:6–19PubMedCrossRef
5.
go back to reference Dolezel M, Odrazka K, Vaculikova M et al (2010) Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 186:197–202PubMedCrossRef Dolezel M, Odrazka K, Vaculikova M et al (2010) Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 186:197–202PubMedCrossRef
6.
go back to reference Fietkau R, Budach W, Zamboglou N et al (2012) Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. The DEGRO-QUIRO trial. Strahlenther Onkol 188:5–11PubMedCrossRef Fietkau R, Budach W, Zamboglou N et al (2012) Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. The DEGRO-QUIRO trial. Strahlenther Onkol 188:5–11PubMedCrossRef
7.
go back to reference Hentschel B, Oehler W, Strauß D et al (2011) Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer. Strahlenther Onkol 187:183–190PubMedCrossRef Hentschel B, Oehler W, Strauß D et al (2011) Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer. Strahlenther Onkol 187:183–190PubMedCrossRef
8.
go back to reference Horwich A, Hugosson J, Reijke T de et al (2013) Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 24:1141–1162PubMedCrossRef Horwich A, Hugosson J, Reijke T de et al (2013) Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 24:1141–1162PubMedCrossRef
9.
go back to reference Leitlinienprogramm Onkologie der AWMW, Deutschen Krebsgesellschaft e. V. und Deutschen Krebshilfe e. V. (eds) (2011) S3-Leitlinie zum Prostatakarzinom, 2011; Version 2.0, Sept. 2011. Berlin Leitlinienprogramm Onkologie der AWMW, Deutschen Krebsgesellschaft e. V. und Deutschen Krebshilfe e. V. (eds) (2011) S3-Leitlinie zum Prostatakarzinom, 2011; Version 2.0, Sept. 2011. Berlin
10.
go back to reference Matzinger O, Duclos F, Bergh A van den et al (2009) Acute toxicity of curative radiotherapy for intermediate- and high-risk localized prostate cancer in the EORTC trial 22991. Eur J Cancer 45:2825–2834PubMedCrossRef Matzinger O, Duclos F, Bergh A van den et al (2009) Acute toxicity of curative radiotherapy for intermediate- and high-risk localized prostate cancer in the EORTC trial 22991. Eur J Cancer 45:2825–2834PubMedCrossRef
11.
go back to reference Nguyen PL, Gu X, Lipsitz SR et al (2011) Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517–1524PubMedCentralPubMedCrossRef Nguyen PL, Gu X, Lipsitz SR et al (2011) Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517–1524PubMedCentralPubMedCrossRef
12.
go back to reference Perna L, Fiorino C, Cozzarini C et al (2009) Sparing the penile bulb in the radical irradiation of clinically localized prostate carcinoma: a comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and helical tomotherapy. Radiother Oncol 93:57–63PubMedCrossRef Perna L, Fiorino C, Cozzarini C et al (2009) Sparing the penile bulb in the radical irradiation of clinically localized prostate carcinoma: a comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and helical tomotherapy. Radiother Oncol 93:57–63PubMedCrossRef
13.
go back to reference Resnick MJ, Koyama T, Kang-Hsien F et al (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436–445PubMedCentralPubMedCrossRef Resnick MJ, Koyama T, Kang-Hsien F et al (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436–445PubMedCentralPubMedCrossRef
14.
go back to reference Robert Koch-Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (eds) (2012) Krebs in Deutschland 2007/2008, 8. überarbeitete und aktualisierte Herausgabe, Robert Koch Institut 2012, Bibliographische Information der Deutschen Bibliothek; Berlin Robert Koch-Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (eds) (2012) Krebs in Deutschland 2007/2008, 8. überarbeitete und aktualisierte Herausgabe, Robert Koch Institut 2012, Bibliographische Information der Deutschen Bibliothek; Berlin
15.
go back to reference Tzikas A, Karaiskos P, Papanikolaou N et al (2011) Investigating the clinical aspects of using CT vs CT-MRI images during organ delineation and treatment planning in prostate cancer. Technol Cancer Res Treat 10:231–242PubMed Tzikas A, Karaiskos P, Papanikolaou N et al (2011) Investigating the clinical aspects of using CT vs CT-MRI images during organ delineation and treatment planning in prostate cancer. Technol Cancer Res Treat 10:231–242PubMed
16.
go back to reference Slotman BJ, Cottier B, Bentzen SM et al (2005) Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol 75:349–354PubMed Slotman BJ, Cottier B, Bentzen SM et al (2005) Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol 75:349–354PubMed
17.
go back to reference Wolff D, Stieler F, Welzel G et al (2009) Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol 93:226–233PubMedCrossRef Wolff D, Stieler F, Welzel G et al (2009) Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol 93:226–233PubMedCrossRef
18.
go back to reference Zabel-du Bois A, Milker-Zabel S, Henzel M et al (2012) Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery. QUIRO-DEGRO trial. Strahlenther Onkol 188:769–776CrossRef Zabel-du Bois A, Milker-Zabel S, Henzel M et al (2012) Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery. QUIRO-DEGRO trial. Strahlenther Onkol 188:769–776CrossRef
19.
go back to reference Zelefsky MJ, Levin EJ, Hunt M et al (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70:1124–1129PubMedCrossRef Zelefsky MJ, Levin EJ, Hunt M et al (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70:1124–1129PubMedCrossRef
Metadata
Title
Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer
The DEGRO-QUIRO trial
Authors
Prof. Dr. L. Keilholz
J. Willner
H.-J. Thiel
N. Zamboglou
H. Sack
W. Popp
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 1/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0440-0

Other articles of this Issue 1/2014

Strahlentherapie und Onkologie 1/2014 Go to the issue